NCT07093073View on ClinicalTrials.gov

Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 23, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2029

Conditions
B Cell Lymphoma
Interventions
DRUG

ssCART-19

Lymphodepletion preconditioning is required prior to CAR-T cell therapy. Lymphodepletion will be performed using a regimen of cyclophosphamide (250-500 mg/m²) and fludarabine (25-30 mg/m²), each administered for 3 consecutive days.

Trial Locations (3)

300190

RECRUITING

Tianjin First Central Hospital, Tianjin

Unknown

RECRUITING

Hebei Yanda Lu Daopei Hospital, Hebei

RECRUITING

Tongji Hospital of Tongji University, Shanghai

All Listed Sponsors
lead

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

INDUSTRY